BMY 28271

prodrug of BMY 28232

Also Known As:

7-(2-(2-aminothiazolyl)-2-hydroxyiminoacetamido)-3-(1-propenyl)-3-cephem-4-carboxylic acid acetoxyethyl ester; BMY-28271; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)(hydroxyimino)acetyl)amino)-8-oxo-3-(1-propenyl)-, 1-(acetyloxy)ethyl ester, (6R-(3(Z),6alpha,7beta(Z)))-

Networked: 3 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Related Diseases

1.	Infections 11/01/1988 - "BMY-28271 showed good oral bioavailability (66%) and good in vivo efficacy in mice against infections of Staphylococcus aureus Smith (PD50, 0.68 mg/kg) and Escherichia coli Juhl (0.54 mg/kg)." 04/01/1990 - "Orally administered BMY-28271 had a good therapeutic effect on systemic infections with S. " 04/01/1990 - "aureus Smith infection: the efficacy of BMY-28271 was 80 to 90 times higher than that of cefixime or cefteram."
2.	Body Weight (Weight, Body) 04/01/1989 - "Oral 50% protective doses (in milligrams per kilogram of body weight) of 0.65 and 0.72 for Staphylococcus aureus Smith, 0.9 and 1.2 for Escherichia coli Juhl, 1.6 and 1.6 for Proteus vulgaris, and 18.9 and 14.3 for Enterobacter cloacae were obtained for BMY-28271 and BMY-28257, respectively."

Related Drugs and Biologics

1.	Cefixime (Suprax)
2.	cefteram
3.	Therapeutic Uses